Description: Gain a high-level understanding on how long-duration targeted improvement (LDTI) impacts insurance products and earnings. Explore highlights on secondary impacts to companies due to additional complexity of LDTI, such as a need for a source of earnings analysis. Then dive into the details and hear an explanation on how earnings emergence differs for each type of life and annuity product impacted by LDTI. Finally, discuss the impact -to-earnings volatility under LDTI for each product type. Close the session by connecting how the investor story changes with all the impacts discussed during the session.You should walk away with a good understanding of LDTI earnings emergence, which is a topic that has very limited thought leadership available today.

Description: In this session, presenters will share the impacts of transition to IFRS 17 on equity and various KPIs across insurance companies (Life & P&C), as well as share some observations of what the IFRS 17 landscape looks like across different global regions. The session will conclude with lessons learned and expectations for emerging practices under IFRS 17 globally.

Description: With LDTI in the rear-view mirror for 2023 adopters, and 2025 adopters still working to meet the requirements before reporting on an LDTI basis for the first time at year-end 2025, there remain many opportunities and challenges for all companies subject to LDTI. These may include further enhancements to modeling, improvements in end-to-end processes (such as automation and reducing the close financial timeline), development of robust management reporting and analysis frameworks, and enhancements to financial planning and analysis under LDTI.

Description: Gain an overview of the requirements for the new asset adequacy Actuarial Guideline 53 (AG53) guideline for complex assets. You will discover helpful insights and considerations for multi-scenario testing and sensitivity testing as well as approaches to developing attribution analyses for complex assets. You will also receive insights from any published regulatory materials that help describe what worked well and what needs improvement based on the initial AG 53 submissions from year-end 2022.

Description: As companies have reported their latest financials for 2023, LDTI is in its full swing for the public companies. Under US GAAP reinsurance accounting methods can be daunting. Add onto this legacy practices related to reinsurance reporting and this may lead to significant unwinding and implementation efforts. This session will discuss industry practices commonly applied to US GAAP reinsurance reported balances such that LDTI adopters can gather deeper insights into the LDTI impact. Specifically, the session will explain the two most popular methods to value reinsurance under LDTI, methods applying a direct measurement of the reinsurance net cost and a method that recognizes ceded asset balances and a cost of reinsurance (“CoRe”). The session will present simplified direct and ceded models to demonstrate how the actuarial balances under LDTI impact GAAP book profits for different underlying products and reinsurance types.

Description: Both LDTI and IFRS 17 have introduced numerous new metrics with most companies having only crossed the finish line, just complying with what's needed for reporting due the complexity and large amounts of data required to simply comply. How do you leverage all the work you did to get proper business insights across the organization that tie back to these reporting metrics? This presentation covers a perspective of pain points faced in getting over the the hurdle in complying with LDTI and IFRS 17, upcoming hurdles, emerging KPIs, as well as how to best manage the data, technology, and processes to produce the analysis around these KPIs efficiently.

Description: This article helps companies better understand the currently proposed upcoming VM-22 regulation by comparing the VM-22 measurement model to LDTI MRBs. The article highlights key considerations as companies plan for adoption of these two measurement models. These considerations should help inform a company’s strategy related to the business impacted by these standards.

Description: The 2020 edition of the Valuation Manual permits mortality data aggregation thereby enhancing credibility but also has accompanying requirements and addresses calculation of company experience rates.

Description: Attend this webcast to learn more on how to navigate managing ESG principles in the new normal of a post-COVID world. Enhance your ESG insights in a post-pandemic landscape.

Description: IUL continues to be the strongest selling UL product. Companies have great profit/pricing expectations, but are those results being achieved? Learn about potential areas of underperformance for IUL including behavior related issues, hedging inefficiency, and mortality issues. The session will also discuss ways to monitor these risks and discuss different means to address potential issues of underperformance in hedging, pricing and in force earnings.